Sunshine Biopharma (SBFM) Non Operating Income (2012 - 2026)
Sunshine Biopharma (SBFM) posted Non Operating Income of $151728.0 for Q1 2026, up 164.07% on a QoQ basis from $57458.0 in Q4 2025, and up 100.12% year-over-year from $75818.0 in Q1 2025.
Sunshine Biopharma (SBFM) Non Operating Income (2012 - 2026) Analysis & Trends
Sunshine Biopharma's Non Operating Income history runs 14 years deep, the most recent figure standing at $151728.0 for Q1 2026.
- Quarterly Non Operating Income rose 100.12% year-over-year to $151728.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $349196.0 (down 8.26% YoY) and the FY2025 annual result came in at $273286.0, down 38.33% from the prior year.
- Non Operating Income was $151728.0 for Q1 2026 at Sunshine Biopharma, up from $57458.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $430285.0 in Q2 2024 and bottomed at -$249227.0 in Q4 2024.
- A 5-year average of $118075.3 and a median of $123767.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income soared 1442.82% — and 2024, when it plunged 258.28%.
- Sunshine Biopharma's Non Operating Income stood at $84599.0 in 2022, then jumped by 86.13% to $157464.0 in 2023, then plunged by 258.28% to -$249227.0 in 2024, then surged by 123.05% to $57458.0 in 2025, then jumped by 164.07% to $151728.0 in 2026.
- Business Quant data shows SBFM's Non Operating Income at $151728.0 in Q1 2026, $57458.0 in Q4 2025, and $65355.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Sunshine Biopharma | 750,608.81 | -6.16 Mn | 2.18 Mn | 151,728.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 151,728.00 |
| Dec 31, 2025 | 57,458.00 |
| Sep 30, 2025 | 65,355.00 |
| Jun 30, 2025 | 74,655.00 |
| Mar 31, 2025 | 75,818.00 |
| Dec 31, 2024 | -249,227.00 |
| Sep 30, 2024 | 123,767.00 |
| Jun 30, 2024 | 430,285.00 |
| Mar 31, 2024 | 89,141.00 |
| Dec 31, 2023 | 157,464.00 |
| Sep 30, 2023 | 168,944.00 |
| Jun 30, 2023 | 199,457.00 |
| Mar 31, 2023 | 172,821.00 |
| Dec 31, 2022 | 84,599.00 |
| Sep 30, 2022 | 260,961.00 |
| Jun 30, 2022 | 156,924.00 |
| Mar 31, 2022 | -12,870.00 |
| Dec 31, 2021 | 946,747.00 |
| Sep 30, 2021 | -3.54 Mn |
| Jun 30, 2021 | -2.49 Mn |